首页> 外文期刊>Cancer: A Journal of the American Cancer Society >Superselective High-Dose Cisplatin Infusion With Concomitant Radiotherapy in Patients With Advanced Cancer of the Nasal Cavity and Paranasal Sinuses A Single Institution Experience
【24h】

Superselective High-Dose Cisplatin Infusion With Concomitant Radiotherapy in Patients With Advanced Cancer of the Nasal Cavity and Paranasal Sinuses A Single Institution Experience

机译:超选择性大剂量顺铂输注并伴随放疗对晚期鼻腔和鼻旁窦癌患者的单一治疗经验

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND :The current study aimed to evaluate theefficacy of superselective high-dose cisplatin ifu- sion with concomitant radiotherapy (RADPLAT) for previously untreated patients with advanced cancer of the nasal cavity and paranasal sinuses. METHODS: Between October 1999 and December 2006, 47 patients were given superselective intra-arterial infusions of cisplatin (100-120 mg/m2 per week) with simultaneous intravenous infusions of thiosulfate to neutralize cisplatin toxicity and conventional external-beam radiotherapy (65-70 grays). RESULTS: There were 7 patients (14.9%) diagnosed with T3, 22 (46.8%) with T4a, and 18 (38.3%) with T4b disease. During the median follow-up period of 4.6 years, the 5-year local progression-free survival rate was 78.4% for all patients (n = 47), 69.0% for patients with T4b disease (n-18), and 83.2% for patients with
机译:背景:本研究旨在评估超选择性大剂量顺铂联合放疗(RADPLAT)对先前未经治疗的鼻腔和鼻旁鼻窦癌患者的疗效。方法:1999年10月至2006年12月,对47例患者进行了顺铂超选择性动脉内输注(每周100-120 mg / m2),同时同时静脉注射硫代硫酸盐以中和顺铂毒性和常规的体外放射疗法(65-70)灰色)。结果:7例患者(14.9%)被诊断为T3,22例(46.8%)被诊断为T4a,18例(38.3%)被诊断为T4b。在4.6年的中位随访期内,所有患者(n = 47)的5年局部无进展生存率分别为78.4%,T4b疾病患者(n-18)的69.0%和83.2%

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号